Automatically translated.View original post

Insulin and GLP-1 receptor agonists

Insulin Learning Last 🫡

We summarize the combination drugs of GLP-1 receptor agonists and insulin.

I have the impression that GLP-1 receptor agonists have come to be used frequently in recent years, but how does it work when combined with insulin?

First of all, the big difference between insulin and combination drugs is indications for type 1 diabetes.

GLP-1 is a drug that stimulates insulin secretion, so it cannot be expected to be effective in type 1 diabetes mellitus where insulin is insufficient in the first place.

Side effects such as digestive symptoms are also a concern.

On the other hand, it is characteristic that it is difficult to become low blood sugar and that you can expect weight loss.

have similar characteristics

Let's compare "ultra-fast-acting type + long-acting type insulin" and "GLP-1 receptor agonist + long-acting type insulin."

From Novo Nordisk,

· "Rizodeg" (super fast-acting type + sustained-acting type)

Zoltophy (GLP-1 receptor agonist + long-acting)

are sold. Be careful not to mix them up because they look very similar.

As a difference in action,

In Rizodeg, ultra-fast-acting insulin acts as additional insulin.

In "Zolfi," GLP-1 receptor agonists play that role.

· "Lyzodegu" is a combination of insulin, so of course it can also be used for type 1 diabetes. In addition to once a day, it can also be used twice a day just before meals in the morning and evening. Therefore, while it is easy to control high blood sugar by meals, it can not correspond to lunch, so if necessary, an additional super fast-acting type is required.

Since "Zortofi" can be used at the same timing regardless of meals, it has the advantage of being easy to schedule, such as when administered by a caregiver.

• • • •

That was pharmacist Noriko (• ᴗ • و (و "

In this account, content that is easy for new pharmacists to stumble and

Things that veteran pharmacists wonder about once. There are pharmacists, etc.

We are surely providing useful information at dispensing pharmacies.

Regarding learning, it is mainly a post as a study account of my own pharmacist.

Even if you are in the pharmacy work, you can learn quickly with videos and slides in the gap time, so please check it out if you like 👍

If you have any symptoms that you are concerned about, please be sure to consult a specialist such as a doctor. * The content of this transmission is intended to "output learning" about medical care and health, and is not intended for individual diagnosis or treatment.

Please understand that we do not answer personal questions.

Please understand in advance that we will not be liable for any troubles or damages caused by referring to the information on this account.

2025/10/12 Edited to

... Read more私自身、糖尿病治療薬の学びを進める中で、インスリンとGLP-1受容体作動薬の組み合わせにはとても興味を持ちました。特に、最近よく目にするゾルトファイ配合注射は、その使いやすさと低血糖リスクの低さが大きな魅力だと感じています。例えば、高齢の患者さんや介護を要する方には、食事のタイミングに合わせる必要がなく決まった時間で投与ができるため、服薬のスケジュール管理がしやすいのが利点です。 また、GLP-1受容体作動薬には体重減少効果も期待されており、肥満と糖尿病が合併しているケースでは、インスリン単独よりも有効な治療選択として注目されています。一方で、消化器症状など副作用も注意が必要であるため、患者さんの体調や生活スタイルに合った薬剤選択が大切だと実感しました。薬局で服薬指導を行う際は、副作用の説明や自己注射の操作指導に時間を割くことも多いです。 個人的には、超速効型インスリン+持効型インスリンの配合薬『ライゾデグ』も扱っていますが、食事の内容や時間が不規則な方には、速やかな血糖コントロールが期待できるため、患者さんのライフスタイルに合わせて選択肢を提案できる点がプロとしてのやりがいにつながっています。どちらの配合薬も特徴的で、間違えやすい見た目の類似点から、調剤・服薬指導の際はラベルや製品名の確認に特に注意しています。 このように、インスリンとGLP-1受容体作動薬の配合薬は、それぞれのメリット・デメリットを理解し、患者さん個々の治療目標や生活背景に応じて適切に使い分けることが重要です。薬剤師の立場から、今後も最新の情報をキャッチアップして、患者さんに最適なアドバイスができるよう努めていきたいと思います。